UNSPSC 51311606: Mepyramine hydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular structure C17H23N3O.CLH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5T3R4P0I14 chemically known as 1,2-ethanediamine, n1-((4-methoxyphenyl)methyl)-n2,n2-dimethyl-n1-2-pyridinyl-, hydrochloride (1:1), but more commonly known as mepyramine hydrochloride, which bears US NIH Compound Identifier 80139. European Medicines Agency schedules Mepyramine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB14515MIG.

Most nations, for tariff and trade purposes, schedule mepyramine hydrochloride under HS 29333999. SMILES: CN(C)CCN(CC1CCC(CC1)OC)C2CCCCN2.CL.

UNSPSC 51311606 Mepyramine hydrochloride, a Commodity code, nominally covers a single pharmaceutical compound, but the recent state and local procurement activity tagged under this code shows a material mismatch with the pharmaceutical scope. Seminole County, Florida's solicitation IFB60459723LAS, posted June 30, 2026, seeks 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding — a procurement rooted in emergency medical response and community health infrastructure rather than the antihistamine the code name denotes. State and local procurement offices occasionally misclassify pharmaceutical and medical-supply solicitations across related commodity codes when the primary buying signal centers on the application (opioid overdose reversal, drug disposal systems) rather than the chemical compound itself. The work involves quarterly delivery logistics to a single Seminole County location, with electronic bid submission, fixed-fee pricing, workers' compensation and commercial general liability insurance requirements, and a two-year initial term plus one-year renewal option.

Seminole County is the sole issuing body present in the recent opportunity record for this code, and Florida is the only state showing current activity. The naloxone and drug deactivation systems solicitation carries a July 26, 2023 response deadline (note: the posting date of June 30, 2026 appears to be a data entry error given the 2023 deadlines in the opportunity details). The procurement includes probationary termination rights and potential FEMA funding, introducing compliance requirements tied to the Clean Air Act and Federal Water Pollution Control Act. E-Verify and drug-free workplace certification are mandatory. The code shows limited recent activity and the substance mismatch suggests that vendors pursuing state and local naloxone and drug-deactivation-system contracts may need to monitor broader medical-supply and pharmaceutical UNSPSC families rather than rely solely on this commodity classification.